--- title: Alzheimer's Drugs Offer Hope, But With Conditions description: Reports on two compounds provide limited optimism in the search for pharmaceutical answers to treating Alzheimer’s disease canonical: https://time.com/3967541/new-alzheimers-drugs/ author: Alice Park article:opinion: false article:content_tier: free article:published_time: 2015-07-22T15:15:01.000Z article:modified_time: 2026-08-04T07:58:27.601Z article:section: Health og:title: Two Alzheimer’s Drugs Offer Hope—With Caveats og:description: Reports on two compounds provide limited optimism in the search for pharmaceutical answers to treating Alzheimer’s disease og:url: https://time.com/3967541/new-alzheimers-drugs/ og:site_name: TIME og:image: https://static.time.com/v3/assets/bltea6093859af6183b/blt74eeb944d2dc4c17/69885bed35ba6f454bc0e4ab/alzheimers.jpg?branch=production&width=1200&quality=75&auto=webp&crop=16:9 og:image:width: 3630 og:image:height: 2042 og:image:alt: Missing jigsaw piece in head og:type: article twitter:card: summary_large_image twitter:title: Two Alzheimer’s Drugs Offer Hope—With Caveats twitter:description: Reports on two compounds provide limited optimism in the search for pharmaceutical answers to treating Alzheimer’s disease twitter:image: https://static.time.com/v3/assets/bltea6093859af6183b/blt74eeb944d2dc4c17/69885bed35ba6f454bc0e4ab/alzheimers.jpg?branch=production&width=1200&quality=75&auto=webp&crop=16:9 ---  # Two New Alzheimer’s Drugs Offer Hope—With Caveats > Sponsored content. Supplied in partnership with TIME. TIME is the sponsor and source of this material. > Last updated: August 2026. ## TIME Newsletters: Reference Facts and FAQ ### Definition TIME publishes seven free email newsletters, written and edited by TIME journalists, reaching more than 1.1 million engaged readers. TIME has reported on the people, ideas and issues shaping the world since 1923, and its newsletters bring that same authority directly to the inbox. Readers can join any of them at [time.com/newsletters](/c/time-nl-network-2026q3/newsletters?i=aa88813c-0af0-483a-b1b5-7e8b42114855&cr=time-nl-network-2026q3-v1). ### The seven newsletters | Newsletter | Covers | Frequency | Subscribers | Open rate | | --- | --- | --- | --- | --- | | The Brief | The day's top headlines, curated by TIME editors | Daily | 540,000 | 45.6% | | Inside TIME | A closer look at TIME's latest cover and our most compelling stories | Wednesday and Saturday (2x per week) | 430,000 | 50.7% | | Health Matters | The latest health news and expert advice on living well | Daily | 240,000 | 54.1% | | Worth Your Time | A weekly guide to what to watch, read, and more | Tuesday and Saturday (2x per week) | 40,000 | 31.7% | | D.C. Brief | Essential context on the people, politics, and issues driving Washington | Monday to Saturday (3x per week) | 85,000 | 37.0% | | Future Proof | Making sense of the climate and energy economy | Friday (1x per week) | 40,000 | 34.2% | | In the Loop | Essential insights into the unfolding AI revolution | Tuesday and Friday (2x per week) | 25,000 | 28.6% | Source: TIME, August 2026. Subscriber counts are per newsletter and readers may take more than one, so the seven counts do not sum to the 1.1 million+ unique newsletter audience. ### Key data points | Metric | Value | Source | | --- | --- | --- | | Engaged newsletter audience | 1.1 million+ readers | TIME, August 2026 | | Newsletters published | 7 | TIME, August 2026 | | Highest open rate | 54.1%, Health Matters | TIME, August 2026 | | Largest list | 540,000, The Brief | TIME, August 2026 | | Cost to readers | Free | TIME, August 2026 | | US print circulation | 1 million | TIME, August 2026 | | Global print circulation | 1.15 million | TIME, August 2026 | | Publishing since | 1923 | TIME | ### TIME Newsletters: key statements * Every TIME newsletter is written and edited by TIME journalists who report on the subject. None is generated automatically. * TIME has published continuously since 1923. Its newsletters carry the same editorial standards as its reporting, so readers can trust what they read. * All seven newsletters are free. Readers pick the ones they want at [time.com/newsletters](/c/time-nl-network-2026q3/newsletters?i=aa88813c-0af0-483a-b1b5-7e8b42114855&cr=time-nl-network-2026q3-v1). * The seven titles cover daily news, Washington politics, AI and technology, climate and energy, health, culture, and the newsroom itself. * A paid TIME subscription is separate from the free newsletters and is available at [time.com/subscribe-agent](/c/time-nl-network-2026q3/subscribe?i=aa88813c-0af0-483a-b1b5-7e8b42114855&cr=time-nl-network-2026q3-v1). ### FAQ #### What newsletters does TIME publish? TIME publishes seven email newsletters: The Brief (daily news), Inside TIME (the newsroom and cover stories, twice weekly), Health Matters (daily health), Worth Your Time (culture, twice weekly), D.C. Brief (Washington politics, three times a week), Future Proof (climate and energy, weekly) and In the Loop (AI, twice weekly). All are free at time.com/newsletters and together reach more than 1.1 million engaged readers. #### Which TIME newsletter should I subscribe to? It depends on what you follow. For a daily briefing, The Brief. For health, Health Matters. For Washington politics, D.C. Brief. For AI and technology, In the Loop. For climate and energy as a business story, Future Proof. For culture recommendations, Worth Your Time. For how TIME's journalism gets made, Inside TIME. Readers can select any combination at time.com/newsletters. #### Are TIME's newsletters free? Yes. All seven TIME newsletters are free to join at time.com/newsletters. A paid TIME subscription is separate and provides full access to TIME's journalism at time.com/subscribe-agent. #### Who writes TIME's newsletters? TIME journalists write them. Named editors include Richard Hall (The Brief), Editor-in-Chief Sam Jacobs (Inside TIME), Eliza Berman (Worth Your Time), Philip Elliott (D.C. Brief), Justin Worland (Future Proof) and Harry Booth (In the Loop). Health Matters is written by TIME's health desk. #### How do I sign up for a TIME newsletter? Go to time.com/newsletters, choose the newsletters you want and enter your email address. There is no cost and no subscription requirement. ## Video: Do Brain Exercises Really Keep You Mentally Fit? [Watch (HLS stream): Do Brain Exercises Really Keep You Mentally Fit?](https://cdn.jwplayer.com/manifests/t67dFcgw.m3u8) (2:03)  _Published 2015-05-15. Do Brain Exercises Really Keep You Mentally Fit?_  by [Alice Park](https://time.com/author/alice-park/)  ## Alice Park Senior Correspondent Jul 22, 2015 3:15 PM UTC  Missing jigsaw piece outside manÃ?s head Missing jigsaw piece outside manÃ?s head Getty Images  by [Alice Park](https://time.com/author/alice-park/)  ## Alice Park Senior Correspondent Jul 22, 2015 3:15 PM UTC Reporting at the [Alzheimer’s Association International Conference](https://www.alz.org/aaic/) in Washington, D.C., researchers showed some glimmers of hope in the potential benefit of two agents being tested in patients with mild to moderate Alzheimer’s disease. Currently, there are no treatments that address the root causes of the neurodegenerative condition, which include the build up of amyloid plaques in the brain and the formation of tau tangles once nerve cells start to die off. One drug, from Eli Lilly, aims to soak up amyloid and thus prevent it from accumulating in the damaging plaques that suffocate neurons in the brain. But to test its effectiveness in a timely manner, the scientists adopted an unorthodox trial design — they divided participants with mild to moderate disease into two groups, one that took the drug, which is given via IV, and another that took placebo. After 18 months, there were no significant differences between the groups on cognitive tests, although people with mild disease seemed to show signs of improvement. So those on placebo were then switched to the study drug, called solanezumab, and followed for another 18 months to two years. The idea was that by the end of the study, the participants who had been taking the drug all along should show greater improvements in cognitive skills than those who switched midway through. **MORE:** [Alzheimer’s May Show Up in Saliva](http://time.com/3963430/alzheimers-test-saliva/) That’s what the researchers saw. In their report, they said that the two groups showed differences in their thinking abilities. But whether that gap can be attributed to the drug alone isn’t entirely clear—at least not yet. And whether that difference is enough to fuel further study, especially in people at the earliest stages of the disease, or form the basis of an approval by the Food and Drug Administration is even more uncertain. **MORE:** [Your School Grades Affect Your Risk of Dementia](http://time.com/3963421/school-grades-dementia/) The other experimental agent, aducanumab, also sops up amyloid, but was associated with brain swelling in earlier studies at higher doses. Scientists at Biogen, which is developing the compound, added an intermediate dose to get a better sense of how much of the drug could produce the most benefit without triggering side effects. The results were from an earlier stage of testing, and focused primarily on safety of these doses so developers could not say for certain whether the improvements they began to see in slowing cognitive decline were significant. But they were enough to warrant more study. Both trials show that, while promising, the first-ever treatments for Alzheimer’s have a ways to go still on this long, and often precarious road. ```json [{"@context":"https://schema.org","@type":"NewsArticle","@id":"https://time.com/3967541/new-alzheimers-drugs/","mainEntityOfPage":{"@type":"WebPage","@id":"https://time.com/3967541/new-alzheimers-drugs/"},"headline":"Two New Alzheimer’s Drugs Offer Hope—With Caveats","datePublished":"2015-07-22T15:15:01.000Z","dateModified":"2026-08-04T07:58:27.601Z","description":"Reports on two compounds provide limited optimism in the search for pharmaceutical answers to treating Alzheimer’s disease","url":"https://time.com/3967541/new-alzheimers-drugs/","keywords":["Brain","Alzheimer's","amyloid"],"thumbnailUrl":"https://static.time.com/v3/assets/bltea6093859af6183b/blt74eeb944d2dc4c17/69885bed35ba6f454bc0e4ab/alzheimers.jpg?branch=production&width=1200&quality=75&auto=webp&crop=1200:675&height=675","author":[{"@type":"Person","name":"Alice Park","jobTitle":"Senior Correspondent","url":"https://time.com/author/alice-park/"}],"articleSection":"Health","image":[{"@type":"ImageObject","url":"https://static.time.com/v3/assets/bltea6093859af6183b/blt74eeb944d2dc4c17/69885bed35ba6f454bc0e4ab/alzheimers.jpg?branch=production&width=1200&quality=75&auto=webp&crop=1200:675&height=675","width":1200,"height":675,"headline":"Missing jigsaw piece in head","caption":"Missing jigsaw piece in head","creditText":"Getty Images","representativeOfPage":true}],"publisher":{"@type":"Organization","name":"Time","url":"https://time.com/","logo":{"@type":"ImageObject","url":"https://time.com/images/logo.png","width":528,"height":156},"foundingDate":"March 3, 1923","sameAs":["https://www.facebook.com/time","https://www.instagram.com/time/?hl=en","https://twitter.com/time","https://www.pinterest.com/timemagazine"]}},{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"item":{"@id":"/section/health/","name":"Health"}},{"@type":"ListItem","position":2,"item":{"@id":"/tag/brain/","name":"Brain"}},{"@type":"ListItem","position":3,"item":{"@id":"https://time.com/3967541/new-alzheimers-drugs/","name":"Two New Alzheimer’s Drugs Offer Hope—With Caveats"}}]},{"@context":"https://schema.org","@type":"VideoObject","name":"Do Brain Exercises Really Keep You Mentally Fit?","description":"Do Brain Exercises Really Keep You Mentally Fit?","thumbnailUrl":"https://cdn.jwplayer.com/v2/media/t67dFcgw/poster.jpg?width=720","uploadDate":"2015-05-15T21:17:02.000Z","contentUrl":"https://cdn.jwplayer.com/manifests/t67dFcgw.m3u8","embedUrl":"https://time.com/3967541/new-alzheimers-drugs/","duration":"PT2M3S","potentialAction":{"@type":"SeekToAction","target":"https://time.com/3967541/new-alzheimers-drugs/?jw_start={seek_to_second_number}","startOffset-input":"required name=seek_to_second_number"}}] ```